Table 6

Percentage of patients with treatment-emerging adverse events (TEAEs): ≥ 10% incidence and at least twice the incidence seen with placebo

TEAE Placebo (n=130) Venlafaxine ER
37.5 mg (n=140) 75 mg (n=134) 150 mg (n=137)
Constipation 5 8 13 15
Dizziness 14 15 22 31
Dry mouth 4 6 13 17
Infection 4 9 5 12
Nausea 14 22 34 42
Paraesthesiae 2 1 2 10
Sweating 5 9 11 18